The interaction of science and law in protecting the public’s health
Keywords:
postmarket laws, premarket laws, science-law interaction, mechanistic evidenceAbstract
As public health interventions largely eradicated infectious diseases, chronic diseases became the leading causes of morbidity and mortality in developed countries. Too many chronic diseases result from environmental exposures caused by the actions or products of others. My research has addressed how science-law interactions can reduce or prevent diseases caused by others. A recent work, Tragic Failures: How and Why We Are Harmed by Toxic Substances, explores the relations between science and the law 1) in administrative law, which aims to prevent or reduce environmentally triggered diseases, and 2) in the tort or personal injury law, a venue to compensate people who have been harmed by the actions or products of others. While laws guide both institutions, science assists in discovering, understanding, limiting, and mitigating risks. How it is utilized matters. This article first considers the law-science interaction under administrative laws to protect citizens from environmentally triggered diseases or dysfunctions: “When should science be used to identify potential risks to protect the public?” and, “How much and what kinds of scientific evidence should used to reduce or remove risks from products once they are commerce?” Next, the discussion addresses, “How much and what kinds of evidence should the tort law require for plaintiffs to be compensated for injuries caused by others? I suggest a unified approach to address the “how-much-evidence-is-needed-for institutional-responses” in the law. Recent scientific findings hold the promise for quicker identification of toxicants to protect the public health.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.